Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial-Reference-Cited by-同舟云学术

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Published:2013-01 Issue:1 Volume:14 Page:29-37
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Bennouna Jaafar,Sastre Javier,Arnold Dirk,Österlund Pia,Greil Richard,Van Cutsem Eric,von Moos Roger,Viéitez Jose Maria,Bouché Olivier,Borg Christophe,Steffens Claus-Christoph,Alonso-Orduña Vicente,Schlichting Christoph,Reyes-Rivera Irmarie,Bendahmane Belguendouz,André Thierry,Kubicka Stefan

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

2. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study;Saltz;J Clin Oncol,2008

3. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study;Tebbutt;J Clin Oncol,2010

4. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200;Giantonio;J Clin Oncol,2007

5. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study;Kozloff;Oncologist,2009

Cited by 1002 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial;British Journal of Cancer;2024-09-07

2. Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study;BMC Cancer;2024-09-02

3. A Case Report of Unrespectable Liver Metastases from Cancer Rectosigmoid Colon with Survival Greater Than 6 Years and Clinical Benefit after Multidisciplinary Treatment;International Journal of Innovative Science and Research Technology (IJISRT);2024-08-31

4. From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies;International Journal of Molecular Sciences;2024-08-30

5. Integrating Vascular Phenotypic and Proteomic Analysis in an Open Microfluidic Platform;ACS Nano;2024-08-29